

Please type a plus sign (+) inside this box → **+**

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

NOV 07 2002

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

09/771,208

Filing Date

January 26, 2001

First Named Inventor

Juan F. Medrano

Group Art Unit

1653

Examiner Name

Not yet Assigned

Attorney Docket Number

407T-923710US

b7c
S27

NOV 08
2002

TECH CENTER 1600/2002

RECEIVED

ENCLOSURES (check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Copy of Executed Assignment	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Executed Declaration	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Drawings	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Letter to Official Draftsperson	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Substitute Specification	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Executed Power of Attorney and 3.73b Certificate	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input checked="" type="checkbox"/> Sequence Listing	<input type="checkbox"/> receipt acknowledgment postcard
<input type="checkbox"/> Information Disclosure Statement	<input checked="" type="checkbox"/> Diskette	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input checked="" type="checkbox"/> Sequence Listing Amendment	
<input checked="" type="checkbox"/> Copy of Notice to Comply		
<input checked="" type="checkbox"/> Copy of Response to Comply		

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Tom Hunter, Reg. No. 38,498,	Quine Intellectual Property Law Group P.C.
Signature		
Date	November 4, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: **November 4, 2002**

Typed or printed name	Chianti Appling	Date	11/04/2002
Signature			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY2002

NOV 07 2002

Patent fees are subject to annual revision.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

TOTAL AMOUNT OF PAYMENT (\$)

Complete If Known

Application Number	09/771,208
Filing Date	January 26, 2002
First Named Inventor	Juan F. Medrano
Examiner Name	Not yet Assigned
Group / Art Unit	1653
Attorney Docket No.	407T-923710US

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number **50-0893**
 Deposit Account Name Quine Intellectual Property Law Group, P.C.

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. Payment Enclosed:

Check Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
106 310	206 155	Design filing fee	
107 480	207 240	Plant filing fee	
108 690	208 345	Reissue filing fee	
114 150	214 80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES

Total Claims	-20**	=	X	=	Fee from below	Fee Paid
Independent Claims	- 3**	=	X	=		
Multiple Dependent						

**or number previously paid, if greater; For Reissues, see below

Large Entity Small Entity

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 78	209 39	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	460.00
118 1440	218 720	Extension for reply within fourth month	
128 1960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 300	220 150	Filing a brief in support of an appeal	
121 260	221 130	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 430	243 215	Design issue fee	
144 580	244 290	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Petitions related to provisional applications	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 690	246 345	Filing a submission after final rejection (37 CFR 1.129(a))	
149 690	249 345	For each additional invention to be examined (37 CFR 1.129(b))	
Other fee (specify) _____			
Other fee (specify) _____			
* Reduced by Basic Filing Fee Paid			SUBTOTAL (3) (\$)

460.00

SUBMITTED BY

Typed or Printed Name

Tom Hunter

Complete (if applicable)

Reg. Number 38,498

Signature

Date 11/04/2002

Deposit Account User ID

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on this date: November 4, 2002

Typed or Printed Name

Chianti Appling

Signature

Date

11/04/2002



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: 1401 L Street, N.W., Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/771,208	01/26/2001	Juan F. Medrano	407T-923710US	7351

NOV 07 2002

Tom Hunter
SKJERVEN MORRILL MacPHERSON LLP
Suite 700
25 Metro Drive
San Jose, CA 95110-1349

7590 07/03/2002

RECEIVED
by Docket Dept.

JUL 15 2002

Skjerven, Morrill LLP

EXAMINER

SHUKLA, RAM R

ART UNIT

PAPER NUMBER

1632

DATE MAILED: 07/03/2002

RECEIVED
NOV 08 2002

TECH CENTER 1600
11293 1600/2960

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

JUL 22 2002 Transferred to Tom Hunter
Quine Intellectual Property Law Group, PC

m-9233
11293

DUE: _____

DUE: _____

DUE: _____

DATE: 7/15/02

YES/NO

Restriction
DUE August 2, 2002

VERIFICATION OF DOCKETED DATES:
Office Action by Attorney: _____
Docket System by Secretary: _____
INB: Must be completed immediately upon receipt

DOCKETED
7/24/02

Office Action Summary

NOV 07 2002

Application No.

09/771,208

Applicant(s)

MEDRANO ET AL

Examiner

Ram Shukla

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address.

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 27 February 2002.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-76 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-76 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.

- 4) Interview Summary (PTO-413) Paper No(s) _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: detailed action.

DETAILED ACTION

1. Claims 1-76 are pending.

2. Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Specifically the application fails to comply with CFR 1.821(d), which states:

(d) Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO: " in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

For example, the specification discloses nucleotide sequence on page 24, line 30. However, this sequence is not identified by a sequence identifier and it is not clear whether the sequence has been listed in the sequence listing. Applicants are advised to carefully check the entire specification and list any other unlisted sequence in sequence listing.

For compliance with sequence rules, it is necessary to include the sequence in the "Sequence Listing" and identify them with SEQ ID NO. In general, any sequence that is disclosed and/or claimed as a sequence, i.e., as a string of particular bases or amino acids, and that otherwise meets the criteria of 37 CFR 1.821(a), must be set forth in the "Sequence Listing." (see MPEP 2422.03).

For the response to this office action to be complete, Applicants are required to comply with the Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Election/Restrictions

3. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Art Unit: 1632

- I. Claims 1-7 and 62-63, drawn to a nucleic acid that encodes a gene product which when knocked out produces a high growth phenotype, classified in class 536, subclass 23.1.
- II. Claims 8-22 and 27-36, drawn to a method of producing a knockout animal wherein the expression of Socs-2 gene is inhibited and the animal so produced, classified in class 800, subclass 8.
- III. Claims 8 and 23-26, drawn to a knockout animal in which the expression of another gene, in addition to Socs-2 gene expression, has been inhibited, classified in class 800, subclass 8.
- IV. Claim 37-46, 48, 59 and 60, drawn to a method of screening of an agent that alters a high growth phenotype using an in-vitro cell culture system, classified in class 435, subclass 375.
- V. Claims 37, 47, 48, and 61, drawn to a method of screening of an agent that alters a high growth phenotype using an animal, classified in class 800, subclass 3.
- VI. Claims 48-55 and 58, drawn to a method of screening of an agent that interacts with a Socs-2 nucleic acid in-vitro and alters expression of a high growth phenotype, classified in class 435, subclass 6.
- VII. Claims 48-53 and 56-58, drawn to a method of screening of an agent that interacts with a Socs-2 protein in-vitro and alters expression of a high growth phenotype, classified in class 435, subclass 7.1.
- VIII. Claim 64, drawn to a polypeptide that is encoded by a certain polynucleotide, classified in class 530, subclass 350.
- IX. Claim 65, drawn to an antibody that specifically binds to a certain polypeptide, classified in class 530, subclass 387.1.
- X. Claims 66-71, drawn to a nucleic acid for disrupting a Socs-2 gene, classified in class 435, subclass 320.1.
- XI. Claims 72-76, drawn to an animal cell in which the endogenous Socs-2 has been disrupted, classified in class 435, subclass 325.

Art Unit: 1632

4. The inventions of Groups II and III encompass the limitations of the claim 8. Should any of these groups be elected for prosecution, the invention of claim 8 would be examined to the extent it encompasses the claimed invention.

5. The inventions of Groups IV, V, VI, and VII encompass the limitations of the claim 48. Should any of these groups be elected for prosecution, the invention of claim 48 would be examined to the extent it encompasses the claimed invention.

6. The inventions of Groups IV and V encompass the limitations of the claim 37. Should any of these groups be elected for prosecution, the invention of claim 37 would be examined to the extent it encompasses the claimed invention.

7. The inventions of Groups VI and VII encompass the limitations of the claim 58. Should any of these groups be elected for prosecution, the invention of claim 58 would be examined to the extent it encompasses the claimed invention.

8. Inventions of the groups I and VIII-X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to nucleic acids, polypeptide, antibody and an animal cell that have different structure, have different modes of operation and have different utilities. For example, the physical and chemical characteristics of a nucleic acid are different from those of a protein or an antibody. Likewise, the utility of a nucleic acid is different from those of a protein or an antibody, for example, a nucleic acid is used for making probes that can be used for northern or southern hybridization, whereas protein can be used for enzyme activity studies while an antibody can be used for western blotting or in-situ hybridization. Additionally, the characteristics of an antibody can vary depending upon the epitope or motif used for raising the antibody.

Art Unit: 1632

9. Inventions of groups I and X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to nucleic acids that have different sequence structure, function and utility. The nucleic acid of group I is used for expressing wild type Socs-2 protein whereas the nucleic acid of group X is used for targeted disruption of an endogenous Socs-2 gene.

10. Inventions of the groups II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the invention of group II is drawn to Socs-2 gene knockout animal whereas the knockout animal has an additional gene knocked out. Therefore, the genotype as well as the phenotype and the utilities of the two animals would be different.

11. Inventions of the groups IV to VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to methods that use different components and steps and the steps of one method could not be used to practice another method. For example, the steps of screening for an agent that alters gene expression in vitro would be different from a method of in vivo screening since the in vitro method would not require administration of an agent to an animal. Likewise, the method of screening of compounds that interact with a protein would be different from that of screening method using a nucleic acid due to the difference in structures of nucleic acid and protein. Furthermore, an agent isolated by one method may not be isolated by another method.

Art Unit: 1632

12. Inventions of the groups I, IV and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleic acid of group I are used in practicing the methods of group IV and VI, however, the nucleic acid of group I can be used for practicing multiple methods such as that of groups IV and VI.

13. Inventions of the groups X, II, III and XI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleic acid of group X can be used for practicing materially different processing, such as for making the animal cell, knockout animal or double knockout animal of groups XI, II and III.

14. The methods of groups IV-VII are patentably distinct from the compositions of the groups I-III and VIII-XI because the methods of groups IV-VII can not be used to make the compositions of the groups I-III and VIII-XI.

15. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art shown by their different classification and their recognized divergent subject matter, and because each invention requires a separate, non-coextensive search, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1632

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

When amending claims, applicants are advised to submit a clean version of each amended claim (without underlining and bracketing) according to § 1.121(c).


For instructions, Applicants are referred to

<http://www.uspto.gov/web/offices/dcom/olia/aipa/index.htm>.

Applicants are also requested to submit a copy of all the pending/under consideration claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ram R. Shukla whose telephone number is (703) 305-1677. The examiner can normally be reached on Monday through Friday from 7:30 am to 4:00 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for this Group is (703) 308-4242. Any inquiry of a general nature, formal matters or relating to the status of this application or proceeding should be directed to the Dianiece Jacobs whose telephone number is (703) 305-3388.

Ram R. Shukla, Ph.D.



RAM R. SHUKLA, PH.D
PATENT EXAMINER